Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2017

01-12-2017 | Original Article

The Role and Regulation of the 11 Beta-Hydroxysteroid Dehydrogenase Enzyme System in Patients with Inflammatory Bowel Disease

Authors: M. Hussey, G. Holleran, S. Smith, Mark Sherlock, D. McNamara

Published in: Digestive Diseases and Sciences | Issue 12/2017

Login to get access

Abstract

Introduction

Glucocorticoids are known to modulate a number of immunological responses including counteracting inflammation. Within tissues expressing the glucocorticoid and mineralocorticoid receptors including the colon, glucocorticoid metabolism is regulated by the isoenzymes of 11ß-hydroxysteroid dehydrogenase (11β-HSD). 11β-HSD1 acts as an oxidoreductase converting inactive cortisone into active cortisol, while 11β-HSD2 acts as a dehydrogenase converting active cortisol to inactive cortisone. Hexose-6 phosphate dehydrogenase (H6PDH) is a key regulator of 11β-HSD1 activity via its generation of NADPH. Variations in the 11β-HSD enzyme system in relation to levels of expression and regulation may have a role in IBD. The aim of this study was to investigate possible abnormalities of 11β-HSD enzyme system in the colon of patients with IBD.

Methods

By using quantitative real-time PCR, we investigated the transcription levels of 11β-HSD1 and 2 in colonic tissue from IBD patients and healthy controls undergoing a colonoscopy for disease assessment. Disease activity was recorded using clinical (Mayo Score/Harvey–Bradshaw Index), Biochemical (C-reactive protein), histological, and endoscopic parameters. In addition, transcription levels of H6PDH and the glucocorticoid receptor alpha (GR-α) as well as key pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, Rela (subunit for NF Kappa B)) were later examined among this group, and results were correlated with 11β-HSD2 gene expression. Results and patient demographics were expressed as a mean (and SD), and differences between IBD patients and control groups were analyzed using a Student’s t test or Mann–Whitney U test as appropriate, with a p value of ≤0.05 considered significant. Results were controlled for disease activity as outlined above.

Results

Results have demonstrated a significant downregulation in 11β-HSD2 expression in IBD patients compared with controls (13.8 ± 17.1 au vs. 318.4 ± 521.1 au, p = 0.01), whereas levels of 11β-HSD1 did not appear to vary across the two groups. Among IBD patients, there was a trend toward higher 11β-HSD1 expression in inflamed tissue compared with matched non-inflamed tissue (422.1 ± 944 au vs. 102.2 ± 103.9, P = 0.09). Levels of H6PDH and the GR-α expression did not appear to vary among active inflamed IBD tissue and controls. As a result, we examined the association between pro-inflammatory cytokines and levels of 11β-HSD2 expression. Results showed an upregulation of key pro-inflammatory cytokine mRNA expression (TNF-α, IL-1β, IL-6) during inflammation with an associated downregulation of 11β-HSD2 mRNA expression when compared to controls. Dysregulation in this pathway could have a potential role in IBD pathogenesis and may account for exogenous glucocorticoid resistance in IBD. Further work assessing the role of the 11β-HSD enzyme system in steroid-resistant subjects is warranted.
Literature
1.
go back to reference Zbankova S, Bryndova J, Leden P, Kment M, Svec A, Pacha J. 11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J Gastroenterol Hepatol. 2007;22:1019–1023.CrossRefPubMed Zbankova S, Bryndova J, Leden P, Kment M, Svec A, Pacha J. 11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J Gastroenterol Hepatol. 2007;22:1019–1023.CrossRefPubMed
2.
go back to reference Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am. 2005;34:293–313.CrossRefPubMed Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am. 2005;34:293–313.CrossRefPubMed
3.
go back to reference Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587–609.CrossRefPubMed Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587–609.CrossRefPubMed
4.
go back to reference Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease—mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111–122.CrossRefPubMed Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease—mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111–122.CrossRefPubMed
5.
go back to reference Smith R, Maguire JA, Stein-Oakley AN, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab. 1996;81:3244–3248.PubMed Smith R, Maguire JA, Stein-Oakley AN, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab. 1996;81:3244–3248.PubMed
6.
go back to reference Whorwood CB, Ricketts ML, Stewart PM. Epithelial cell localization of type 2 11 beta hydroxysteroid dehydrogenase in rat and human colon. Endocrinology. 1994;135:2533–2541.CrossRefPubMed Whorwood CB, Ricketts ML, Stewart PM. Epithelial cell localization of type 2 11 beta hydroxysteroid dehydrogenase in rat and human colon. Endocrinology. 1994;135:2533–2541.CrossRefPubMed
7.
go back to reference Bryndova J, Zbankova S, Kment M, Pacha J. Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand J Gastroenterol. 2004;39:549–553.CrossRefPubMed Bryndova J, Zbankova S, Kment M, Pacha J. Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand J Gastroenterol. 2004;39:549–553.CrossRefPubMed
8.
go back to reference Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab. 2008;93:3827–3832.CrossRefPubMedPubMedCentral Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab. 2008;93:3827–3832.CrossRefPubMedPubMedCentral
9.
go back to reference White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18:135–156.PubMed White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18:135–156.PubMed
10.
12.
go back to reference Terao M, Itoi S, Matsumura S, et al. Local glucocorticoid activation by 11β-hydroxysteroid dehydrogenase 1 in keratinocytes. Am J Pathol. 2016;186:1499–1510.CrossRefPubMed Terao M, Itoi S, Matsumura S, et al. Local glucocorticoid activation by 11β-hydroxysteroid dehydrogenase 1 in keratinocytes. Am J Pathol. 2016;186:1499–1510.CrossRefPubMed
13.
go back to reference Ergang P, Vytáčková K, Svec J, Bryndová J, Mikšík I, Pácha J. Upregulation of 11β-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat. J Steroid Biochem Mol Biol. 2011;126:19–25.CrossRefPubMed Ergang P, Vytáčková K, Svec J, Bryndová J, Mikšík I, Pácha J. Upregulation of 11β-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat. J Steroid Biochem Mol Biol. 2011;126:19–25.CrossRefPubMed
15.
go back to reference McKay L, Cidlowski JA. Molecular control of immune/inflammatory responses; intereactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Edocr Rev. 1999;20:435–459. McKay L, Cidlowski JA. Molecular control of immune/inflammatory responses; intereactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Edocr Rev. 1999;20:435–459.
16.
go back to reference Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res. 2001;16:1037–1044.CrossRefPubMed Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res. 2001;16:1037–1044.CrossRefPubMed
17.
go back to reference Takahashi KI, Fukushima K, Sasano H, et al. Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease. Dig Dis Sci. 1999;44:2516–2522.CrossRefPubMed Takahashi KI, Fukushima K, Sasano H, et al. Type II 11beta-hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease. Dig Dis Sci. 1999;44:2516–2522.CrossRefPubMed
18.
go back to reference Stegk JP, Ebert B, Martin HJ, Maser E. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol. 2009;301:104–108.CrossRefPubMed Stegk JP, Ebert B, Martin HJ, Maser E. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol. 2009;301:104–108.CrossRefPubMed
Metadata
Title
The Role and Regulation of the 11 Beta-Hydroxysteroid Dehydrogenase Enzyme System in Patients with Inflammatory Bowel Disease
Authors
M. Hussey
G. Holleran
S. Smith
Mark Sherlock
D. McNamara
Publication date
01-12-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4753-1

Other articles of this Issue 12/2017

Digestive Diseases and Sciences 12/2017 Go to the issue

UNM Clinical Case Conferences

A Fairy Tale with a Hairy Tail

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.